Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6189-6198

  Kim, Jeri ^a   Yang, Peiying ^a   Suraokar, Milind ^a   Sabichi, Anita L ^a   Llansa, Norma D ^a   Mendoza, Gabriela ^a   Subbarayan, Vemparalla ^a   Logothetis, Christopher J ^a   Newman, Robert A ^a   Lippman, Scott M ^a   Menter, David G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; LIPOCALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN D SYNTHASE; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL INTERACTION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HUMAN CELL; LATENT PERIOD; LIGAND BINDING; MALE; MICROENVIRONMENT; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER;

ARACHIDONIC ACID; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GTP-BINDING PROTEINS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; PPAR GAMMA; PROSTAGLANDIN D2; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STROMAL CELLS; TRANS-ACTIVATION (GENETICS);

EID: 22244458283     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4439     Document Type: Article

References (56)

1. Challis JR. Prostaglandins and reproduction-what do knockouts really tell us? Nat Med 1997;3:1326-7.
2. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 2002;68-69:557-73.
3. Aumuller G, Riva A. Morphology and functions of the human seminal vesicle. Andrologia 1992;24:183-96.
4. Bendvold E, Svanborg K, Bygdeman M, Noren S. On the origin of prostaglandins in human seminal fluid. Int J Androl 1985;8:37-43.
5. Eliasson R. Biochemical analyses of human semen in the study of the physiology and pathophysiology of the male accessory genital glands. Fertil Steril 1968;19:344-50.
6. Mann T. Secretory function of the prostate, seminal vesicle and other male accessory organs of reproduction. J Reprod Fertil 1974;37:179-88.
7. Rui H, Thomassen Y, Oldereid NB, Purvis K. Accessory sex gland function in normal young (20-25 years) and middle-aged (50-55 years) men. J Androl 1986;7:93-9.
8. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
9. 2 synthase enzymes and PPARγ are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins Other Lipid Mediat 2003;70:267-84.
10. Tokugawa Y, Kunishige I, Kubota Y, et al. Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. Biol Reprod 1998;58:600-7.
11. Urade Y, Kitahama K, Ohishi H, Kaneko T, Mizuno N, Hayaishi O. Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. Proc Natl Acad Sci U S A 1993;90:9070-4.
12. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9.
13. Soderstrom M, Wigren J, Surapureddi S, Glass CK, Hammarstrom S. Novel prostaglandin D(2)-derived activators of peroxisome proliferator-activated receptor-γ are formed in macrophage cell cultures. Biochim Biophys Acta 2003;1631:35-41.
14. 2 synthase in the fluids of the male genital tract: putative biochemical and physiological functions. Biol Reprod 2002;66:458-67.
15. Zhu H, Ma H, Ni H, Ma XH, Mills N, Yang ZM. Expression and regulation of lipocalin-type prostaglandin D synthase in rat testis and epididymis. Biol Reprod 2004;70:1088-95.
16. Olsson JE. Correlation between the concentration of β-trace protein and the number of spermatozoa in human semen. J Reprod Fertil 1975;42:149-51.
17. Diamandis EP, Arnett WP, Foussias G, et al. Seminal plasma biochemical markers and their association with semen analysis findings. Urology 1999;53:596-603.
18. Subbarayan V, Sabichi AL, Kim J, et al. Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 2004;13:1710-6.
19. Subbarayan V, Xu X, Kim J, et al. Inverse relationship between 15-lipoxygenase-2 and peroxisome proliferator-activated receptor-γ gene expression in normal compared with tumor epithelia. Neoplasia 2005;7:280-93.
20. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-α in normal and malignant prostate cells. Cancer Res 2001;61:2720-6.
21. Brash AR, Boeglin WE, Chang MS. Discovery of a second 15S-lipoxygenase in humans. Proc Natl Acad Sci U S A 1997;94:6148-52.
22. Sarrazin P, Bkaily G, Hache R, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids 2001;64:203-10.
23. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol 1999;162:1278-86.
24. Labonte J, Brochu I, Honore JC, D'Orleans-Juste P. Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Br J Pharmacol 2001;132:934-40.
25. Kempen EC, Yang P, Felix E, Madden T, Newman RA. Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high performance liquid chromatography/electrospray ionization tandem mass specttrometry. Anal Biochem 2001;297:183-90.
26. Yang P, Felix E, Madden T, Fischer SM, Newman RA. Quantitative high performance liquid chromatography/ electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. Anal Biochem 2002;308:168-77.
27. Wigren JJ, Surapureddi S, Olsson AG, Glass CK, Hammarstrom S, Soderstrom M. Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor γ/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. J Endocrinol 2003;177:207-14.
28. 2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995;83:803-12.
29. DiRenzo J, Soderstrom M, Kurokawa R, et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997;17:2166-76.
30. Matsukura S, Jones PA, Takai D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 2003;31:e77.
31. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARγ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 2003;22:4186-93.
32. Kwak YD, Koike H, Sugaya K. RNA interference with small hairpin RNAs transcribed from a human U6 promoter-driven DNA vector. J Pharmacol Sci 2003;93:214-7.
33. Campling BG, Pym J, Galbraith PR, Cole SP. Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. Leuk Res 1988;12:823-31.
34. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the S flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992;11:433-9.
35. Boie Y, Sawyer N, Slipetz DM, Metters KM, Abramovitz M. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995;270:18910-6.
36. 2 receptor. Biochem Biophys Res Commun 2003;307:797-802.
37. Breyer RM. Prostaglandin EP(1) receptor subtype selectivity takes shape. Mol Pharmacol 2001;59:1357-9.
38. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
39. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 1996;804:266-75.
40. Kumagai T, Ikezoe T, Gui D, et al. RWJ-24I947 (MCC-555), a unique peroxisome proliferator-activated receptor-γ ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. Clin Cancer Res 2004;10:1508-20.
41. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator activated receptor γ (trogliazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
42. 2. Cell Growth Differ 2000;11:49-61.
43. Sung SY, Chung LW. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 2002;70:506-21.
44. Yeung F, Chung LW. Molecular basis of co-targeting prostate tumor and stroma. J Cell Biochem Suppl 2002;38:65-72.
45. Gerdes MJ, Larsen M, Dang TD, Ressler SJ, Tuxhorn JA, Rowley DR. Regulation of rat prostate stromal cell myodifferentiation by androgen and TGFβI. Prostate 2004;58:299-307.
46. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:3753-61.
47. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
48. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
49. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9:4792-801.
50. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144:2201-7.
51. Barak Y, Nelson MC, Ong ES. et al. PPAR γ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-95.
52. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
53. Saez E, Olson P, Evans RM. Genetic deficiency in Pparγ does not alter development of experimental prostate cancer. Nat Med 2003;9:1265-6.
54. Jin C, McKeehan K, Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 2003;57:160-4.
55. Jones JR, Shelton KD, Guan Y, Breyer MD, Magnuson MA. Generation and functional confirmation of a conditional null PPAR-γ allele in mice. Genesis 2002;32:134-7.
56. Jiang M, Shappell SB, Hayward SW. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor γ (PPARγ) signaling in prostate cancer. J Cell Biochem 2004;91:513-27.